|1.||Kozaki, Koichi: 5 articles (01/2015 - 01/2009)|
|2.||Hasegawa, Hiroshi: 5 articles (01/2015 - 11/2008)|
|3.||Kobayashi, Yoshio: 4 articles (01/2015 - 11/2008)|
|4.||Toba, Kenji: 4 articles (07/2011 - 11/2008)|
|5.||Obara, Toshimasa: 3 articles (01/2015 - 01/2014)|
|6.||Tanaka, Masamichi: 3 articles (01/2015 - 01/2009)|
|7.||Matsui, Toshifumi: 3 articles (01/2015 - 01/2014)|
|8.||Nagai, Kumiko: 2 articles (01/2015 - 07/2011)|
|9.||Sato, Michiko: 2 articles (01/2015 - 01/2009)|
|10.||Miyagishima, Kei: 2 articles (01/2015 - 01/2014)|
|1.||Prostatic Neoplasms (Prostate Cancer)
09/01/1993 - "A case of prostate cancer with a large abdominal mass effectively treated with a high dose of diethylstilbestrol-diphosphate."
09/01/1989 - "In our studies, as hormonal therapy, maintenance on 100 mg of diethylstilbestrol diphosphate daily was found effective for the treatment of prostatic cancer."
01/01/1982 - "This study investigated the effect of diethylstilbestrol diphosphate (DES-P) on the normal mixed lymphocyte reaction (MLR) and on the MLR in prostatic cancer patients before and during treatment with DES-P. "
10/01/2009 - "This effectiveness was as good as intravenous high-dose diethylstilbestrol diphosphate (DES-DP) treatment which was used as a secondary endocrine therapy for relapsed prostate cancer at our institute previously. "
12/01/2006 - "Absence of Bcl-2 expression favors response to the short-term administration of diethylstilbestrol diphosphate in prostate Cancer."
11/15/1987 - "Clinical trials have utilized intermittent diethylstilbestrol diphosphate (DES) therapy in advanced symptomatic prostatic carcinoma to diminish the morbidity of standard endocrine therapy. "
11/01/2004 - "VX2 carcinoma that had been successively transplanted to the thigh muscles of Japanese White rabbits in the Department of Orthopaedic Surgery of Kyorin University School of Medicine was used. "
10/01/1999 - "Adrenocortical insufficiency associated with long-term high-dose fosfestrol therapy for prostatic carcinoma."
02/01/1991 - "Use of intravenous stilbestrol diphosphate in patients with prostatic carcinoma refractory to conventional hormonal manipulation."
08/15/1990 - "Role of the mitochondrial bc1-complex in the cytotoxic action of diethylstilbestrol-diphosphate toward prostatic carcinoma cells."
02/01/1991 - "In cases with well differentiated adenocarcinoma who discontinued hormonal medication (diethylstilbestrol diphosphate) no patients died of the tumor. "
01/01/1994 - "Phase I trial of high-dose fosfestrol in hormone-refractory adenocarcinoma of the prostate."
03/01/1993 - "[High dose fosfestrol in phase I-II trial for the treatment of hormone-resistant prostatic adenocarcinoma]."
03/01/1996 - "To determine whether long-term oral administration of UFT, a combination of 5-fluorouracil and uracil, in addition to conventional estrogen therapy improved the response and survival of the patients with advanced stage D2 prostate adenocarcinoma, a randomized prospective study was performed with either estrogen alone (Honvan 200 mg/day or presexol 1 mg/day: group A) or estrogen plus UFT (400 mg/day:group B). "
02/01/1993 - "A review of the literature shows that high-dose fosfestrol induces no objective response, a greater than 50% tumor marker decrease in 50% of patients, a subjective improvement in 75% of patients, and cardiovascular complications in 5% of patients. "
11/01/2012 - "A total of 175 CLNs dissected from 56 patients with HNSCC who underwent surgery at Aichi Cancer Center, Kyorin University, Gunma University or Fukushima Medical University, between April 2008 and December 2011 were enrolled. "
10/01/1988 - "250-1600 ng/ml E-DES are measurable after 60-110 min in the plasma of 11 patients suffering from metastatic prostata cancer who have been administered 360 mg fosfestrol orally. "
05/01/1983 - "Tumors grown in diethylstilbestrol diphosphate (DES)-treated rats grew significantly more slowly than tumors grown in orchiectomized animals, and tumors grown in orchiectomized animals grew significantly more slowly than tumors grown in controls (intact male rats). "
10/01/1976 - "This paper includes biologic distributions of 99mTc-Sn-diphosphonate (99mTc-EHDP), 99mTc-Sn-dimercaptosuccinic acid (99mTc-DMSA) and 99mTc-Sn-diethyl stilbestrol diphosphate (99mTc-DSDP, 99mTc-Honvan) as the second report on the tumor affinity to the Ehrlich-bearing mice. "
|5.||Neoplasm Metastasis (Metastasis)
09/01/1993 - "A case is reported about a 75-year-old man with a large abdominal lymph node metastasis caused by prostate cancer effectively treated by a high dose of diethylstilbestrol-diphosphate. "
09/01/1993 - "The usefulness of diethylstilbestrol-diphosphate for prostate cancer patients with lymph node metastasis is emphasized."
06/01/1976 - "Diethylstilbestrol diphosphate is recommended in the treatment of advanced carcinoma of the prostate with soft tissue metastasis. "
06/01/1976 - "Regression of prostatic cancer metastasis by high doses of diethylstilbestrol diphosphate."
09/01/1975 - "Prostatic carcinoma: treatment of liver metastases with intravenous diethylstilbestrol diphosphate."
|9.||Gonadotropin-Releasing Hormone (GnRH)
|4.||Drug Therapy (Chemotherapy)